[go: up one dir, main page]

MX2015009504A - Desloratadine-based pharmaceutical composition to be orally administered, for the treatment of histamine related diseases. - Google Patents

Desloratadine-based pharmaceutical composition to be orally administered, for the treatment of histamine related diseases.

Info

Publication number
MX2015009504A
MX2015009504A MX2015009504A MX2015009504A MX2015009504A MX 2015009504 A MX2015009504 A MX 2015009504A MX 2015009504 A MX2015009504 A MX 2015009504A MX 2015009504 A MX2015009504 A MX 2015009504A MX 2015009504 A MX2015009504 A MX 2015009504A
Authority
MX
Mexico
Prior art keywords
desloratadine
treatment
pharmaceutical composition
orally administered
related diseases
Prior art date
Application number
MX2015009504A
Other languages
Spanish (es)
Other versions
MX388249B (en
Inventor
Daniel Walls Flores Oliver
Rodríguez Hernández Ramón
Montoya Rete Jesús
Original Assignee
Laboratorios Liomont S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Liomont S A De C V filed Critical Laboratorios Liomont S A De C V
Priority to MX2015009504A priority Critical patent/MX388249B/en
Publication of MX2015009504A publication Critical patent/MX2015009504A/en
Publication of MX388249B publication Critical patent/MX388249B/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención consiste de una composición farmacéutica para ser administrada por vía oral y ser utilizada para el tratamiento de problemas relacionados con histamina, sin el uso tanto de lactosa, el uso de un desintegrante, y con la adición de un agente farmacéuticamente aceptable que permita la protección de la desloratadina.The present invention consists of a pharmaceutical composition to be administered orally and used for the treatment of problems related to histamine, without the use of both lactose, the use of a disintegrant, and with the addition of a pharmaceutically acceptable agent that allows Desloratadine protection.

MX2015009504A 2015-07-23 2015-07-23 PHARMACEUTICAL COMPOSITION OF DESLORATADINE TO BE ADMINISTERED ORALLY, FOR THE TREATMENT OF DISEASES RELATED TO HISTAMINE. MX388249B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2015009504A MX388249B (en) 2015-07-23 2015-07-23 PHARMACEUTICAL COMPOSITION OF DESLORATADINE TO BE ADMINISTERED ORALLY, FOR THE TREATMENT OF DISEASES RELATED TO HISTAMINE.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2015009504A MX388249B (en) 2015-07-23 2015-07-23 PHARMACEUTICAL COMPOSITION OF DESLORATADINE TO BE ADMINISTERED ORALLY, FOR THE TREATMENT OF DISEASES RELATED TO HISTAMINE.

Publications (2)

Publication Number Publication Date
MX2015009504A true MX2015009504A (en) 2017-01-23
MX388249B MX388249B (en) 2025-03-12

Family

ID=58404966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009504A MX388249B (en) 2015-07-23 2015-07-23 PHARMACEUTICAL COMPOSITION OF DESLORATADINE TO BE ADMINISTERED ORALLY, FOR THE TREATMENT OF DISEASES RELATED TO HISTAMINE.

Country Status (1)

Country Link
MX (1) MX388249B (en)

Also Published As

Publication number Publication date
MX388249B (en) 2025-03-12

Similar Documents

Publication Publication Date Title
MX2024010140A (en) NEW METHODS.
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
CL2018002727A1 (en) Medicine obtained by combining agonist fxr and arb
MX387322B (en) LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITOR FORMULATIONS.
ECSP17084331A (en) PHARMACEUTICAL FORMULATIONS
PE20151301A1 (en) PHARMACEUTICAL FORMULATIONS RESISTANT TO IMPROPER HANDLING
CR20180253A (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN UNMUNODEFICIENCY VIRUS
MX2019012757A (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION, INCLUDING ENZALUTAMIDE.
DOP2016000254A (en) PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE.
MX2016013236A (en) Immunosuppressant formulation.
CL2019002218A1 (en) Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease.
IL280083A (en) Pharmaceutical dosage form which can be administered orally and has modified release
ECSP19000169A (en) PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT
ECSP16086247A (en) (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
ECSP16086232A (en) (R) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
MX2017013103A (en) METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS.
HK1245131A1 (en) Combination comprising palmitoylethanolamide (pea) and lycopene for use in the treatment of inflammatory diseases
MX2015009504A (en) Desloratadine-based pharmaceutical composition to be orally administered, for the treatment of histamine related diseases.
CL2017000026A1 (en) Pharmaceutical dosage forms
CO2019008347A2 (en) Quick release composition of cinitapride and simethicone and process to prepare it
PE20191820A1 (en) DROPROPIZIN IN COMBINATION WITH AMBROXOL IN THE PHARMACEUTICAL FORM OF SYRUP AND TABLETS
IL261618B (en) Unit doses for immediate release of ghb or of one of the therapeutically acceptable salts thereof, administered orally, and the use thereof to maintain alcohol abstinence.
MX2017001192A (en) PHARMACEUTICAL COMPOSITION OF LORATADINE, PHENYLEFRINE, PARACETAMOL AND AMANTADINE FOR ORAL ADMINISTRATION, FOR THE TREATMENT OF ALOPATHY RELATED TO A COMMON COLD.
TR201720510A2 (en) ORALLY DISINTEGRATING TABLET FORMULATIONS OF IVABRADINE
AR099971A1 (en) UNIT DOSE FORM THAT INCLUDES EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITICAL TABLET THAT INCLUDES DARUNAVIR AND RITONAVIR